Screener
Tarsus Pharmaceuticals, Inc. TARS Income Tax
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Gain on exchange of long-term investments | 2,812 | — | 2,812 | — |
| Other income (expense), net | (281) | (145) | (368) | (226) |
| Total other income (expense), net | 4,073 | 1,844 | 5,580 | 3,004 |
| Provision for income taxes | (2,716) | — | (5,068) | — |
| Net loss | $(18,551) | $(20,340) | $(25,518) | $(45,460) |
| Unrealized gain (loss) on marketable securities and cash equivalents | (259) | (46) | (938) | (140) |
| Comprehensive loss | $(18,810) | $(20,386) | $(26,456) | $(45,600) |
| Net loss per share, basic and diluted | $(0.43) | $(0.48) | $(0.59) | $(1.11) |
Item 1. Financial Statements
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s income tax?
- Tarsus Pharmaceuticals, Inc. (TARS) reported income tax of $2.72M in Q2 2026.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s income tax?
- Over 3 years (2021 to 2024), Tarsus Pharmaceuticals, Inc.'s income tax has grown at a -100.0% compound annual growth rate (CAGR), from $55K to $0.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude